Department of Surgery, University of Tennessee Knoxville Graduate School of Medicine, 1924 Alcoa Hwy Box U-11, Knoxville, TN, 37920, USA.
CQInsights, Knoxville, TN, USA.
Hernia. 2022 Apr;26(2):437-445. doi: 10.1007/s10029-020-02221-7. Epub 2020 May 25.
The use of hernia mesh is a common practice in abdominal wall reconstruction (AWR) operations. The high cost of biologic mesh has raised questions about the value of its use in AWR. Resorbable synthetic mesh may have the potential benefits of biologic mesh, minimizing the need for removal when infected, at a lower cost.
A hernia program has implemented the principles of clinical quality improvement (CQI) to improve patient outcomes. One process improvement attempt was implemented using a newly available resorbable synthetic scaffold. Long-term follow-up was obtained as a part of the CQI process.
A total of 91 patients undergoing AWR were included between 8/11 and 9/15 (49 months). There were 58 female (64%) and 33 male (36%) patients. The average age was 57.2 years (28-80). The average BMI was 34.0 (17.6-53.4). There were 52 patients (57%) with recurrent hernias. Mean hernia defect size was 306.6 cm (24-720) and mean mesh size was 471.7 cm (112-600). Outcomes included a mean length of stay of 7.5 days (0-49), a recurrence rate of 12% (11/91) and a wound complication rate of 27% (25/91). The recurrence rate decreased to 4.5% (3/66) after several improvements, including adopting a transversus abdominus release (TAR) approach, were implemented. There were no mesh-related complications and no mesh removal (partial or total) was required. The mean follow-up length was 42.4 months (0-102).
In this group of patients, an attempt at process improvement was implemented using a resorbable synthetic scaffold for AWR. With no mesh-related complications and no mesh removals required, there was an improvement in value due to the decrease in mesh cost and improved outcomes over time. Long-term follow-up demonstrated the durability of the repair.
在腹壁重建(AWR)手术中,使用疝网片是一种常见的做法。生物网片的高成本引发了人们对其在 AWR 中应用价值的质疑。可吸收合成网片具有生物网片的潜在优势,在感染时最小化了需要移除的需求,且成本更低。
疝病项目已实施临床质量改进(CQI)原则来改善患者的治疗效果。在实施过程中,尝试使用一种新的可吸收合成支架来进行流程改进。作为 CQI 过程的一部分,获得了长期随访结果。
共纳入 8/11 至 9/15 期间(49 个月)接受 AWR 的 91 例患者,其中女性 58 例(64%),男性 33 例(36%),平均年龄 57.2 岁(28-80 岁),平均 BMI 为 34.0(17.6-53.4),52 例(57%)患者为复发性疝,平均疝缺损大小为 306.6cm(24-720),平均补片大小为 471.7cm(112-600)。结果包括平均住院时间 7.5 天(0-49 天),复发率为 12%(11/91),伤口并发症发生率为 27%(25/91)。在采取了一些改进措施,包括采用腹横肌释放(TAR)技术后,复发率降低至 4.5%(3/66)。无网片相关并发症,也无需进行网片移除(部分或全部)。平均随访时间为 42.4 个月(0-102 个月)。
在这组患者中,尝试使用可吸收合成支架进行 AWR,实现了流程改进。由于网片成本降低和治疗效果随时间的改善,无需进行网片相关并发症的处理或移除,从而提高了治疗价值。长期随访结果证实了修复的耐用性。